Results 151 to 160 of about 109,910 (290)
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Irritable Bowel Syndrome [PDF]
Nathani RR, Sodhani S, Goosenberg E.
europepmc +2 more sources
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Background and Purpose Intestinal barrier dysfunction caused by mitochondrial stress, oxidative damage and apoptosis, are hallmarks of dysbiosis‐associated gastrointestinal (GI) disorders. Staurosporine causes downstream features of dysbiosis‐induced epithelial damage.
Fatima Maqoud +9 more
wiley +1 more source
ABSTRACT Introduction The National Bleeding Disorder Foundation (NBDF) Medical and Scientific Advisory Council (MASAC) was formed in 1954 and issues recommendations and advisories pertinent to the bleeding disorders community. MASAC is comprised of > 25 rotating members from different medical disciplines and lived experience experts.
Glaivy Batsuli +15 more
wiley +1 more source
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi +7 more
wiley +1 more source
ABSTRACT Interest in the gut microbiome as a therapeutic target for treating alopecia areata (AA) has grown considerably. However, existing evidence remains limited and inconsistent. Currently, there is insufficient evidence to recommend microbiome‐directed testing and therapies to patients with AA.
Eric McMullen +9 more
wiley +1 more source
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease (CD), is a recognised gastrointestinal disorder. Mycobacterium avium subspecies paratuberculosis (MAP) is implicated in IBD pathogenesis. Persistent exposure and active infections by MAP may contribute to the unsilencing of human endogenous retroviruses (HERV ...
Stefano Ruberto +14 more
wiley +1 more source
Systemic, Lifestyle and Environmental Modifying Factors in the Pathogenesis of Periodontitis
A variety of impacting factors in the pathogenesis of periodontitis exist, including systemic, lifestyle, and environmental factors. This review highlights the manifold mechanistic aspects of the link between the pathogenesis of periodontitis, addressing these numerous factors to supplement the long‐standing knowledge of the progression of the disease.
Groeger Sabine Elisabeth +5 more
wiley +1 more source
The Oral‐Gut Axis: Bidirectional Interactions Between Microbiome and Diseases
This study aims to summarize the mechanisms underlying ectopic colonization of the gut by oral pathobionts and the microbial and host factors that regulate this process. ABSTRACT Increased colonization of typically oral microorganisms is frequently observed in the gut mucosa or lumen of individuals with gastrointestinal disorders, including patients ...
Shinya Ebihara, Nobuhiko Kamada
wiley +1 more source

